Key Performance
More- Earnings Score: N/A
- Momentum Score: 24
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
A securities class action lawsuit has been filed against ARS Pharmaceuticals for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly stated coverage would begin July 1, 2026, while concealing material adverse facts about the actual timeline, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.
10/02/2026, 2:57 PM • GlobeNewswire
A class action lawsuit has been filed against ARS Pharmaceuticals for allegedly providing misleading statements about expanded insurance coverage for its epinephrine nasal spray product (neffy) with CVS Caremark. The company reportedly expressed confidence that coverage would begin July 1, 2026, while failing to adequately disclose risks that the deadline might not be met, potentially impacting summer and back-to-school sales.
10/02/2026, 2:43 PM • GlobeNewswire
A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly misled investors about expected July 1, 2026 coverage, causing shareholders to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.
09/28/2026, 8:19 PM • GlobeNewswire
Rosen Law Firm has filed securities class action lawsuits against Tigo Energy, Inc., AST SpaceMobile, Inc., and ARS Pharmaceuticals, Inc. The Tigo lawsuit alleges the company made materially false statements regarding revenue projections based on an EG4 partnership that would not materially contribute revenue until Q4 2026 at the earliest. Investors who purchased securities during the class periods may be eligible for compensation. Lead plaintiff deadlines vary by case.
09/28/2026, 8:11 PM • GlobeNewswire
Schall, Brown & Schwartz LLP announced a securities fraud class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) for making false and misleading statements regarding timeline issues related to CVS Caremark's addition of neffy to its formulary. The class period spans March 9, 2026 to June 24, 2026, with an October 5, 2026 deadline for investors to participate. Shareholders who suffered losses are encouraged to contact the firm regarding lead plaintiff appointments.
09/24/2026, 9:57 AM • GlobeNewswire
Rosen Law Firm announces class action securities lawsuits against Datavault AI Inc. (DVLT) and ARS Pharmaceuticals Inc. (SPRY), with October 5, 2026 deadline for investors to join. The Datavault AI lawsuit alleges false statements regarding business partnerships, platform activity, and undisclosed connections to a convicted felon. Investors who purchased securities during specified periods may be eligible for compensation.
09/22/2026, 9:55 PM • GlobeNewswire
Rosen Law Firm announces class action securities lawsuits against ARS Pharmaceuticals (SPRY) and Datavault AI (DVLT), with October 5, 2026 deadline for investors to join. ARS Pharmaceuticals is accused of providing misleading statements regarding insurance coverage expansion timeline for its epinephrine spray product neffy through CVS Caremark, allegedly causing investors to purchase shares at artificially inflated prices.
09/22/2026, 9:44 PM • GlobeNewswire
Pomerantz Law Firm has filed a class action lawsuit against ARS Pharmaceuticals (NASDAQ: SPRY) alleging securities fraud. The lawsuit was triggered after ARS announced on June 24, 2026, that it failed to secure expanded insurance coverage for its epinephrine nasal spray product 'neffy' through CVS Caremark by the July 1 deadline. The announcement caused ARS's stock to plummet 23.91% to $8.02 per share on June 25, 2026. Investors have until October 5, 2026, to request appointment as Lead Plaintiff.
09/22/2026, 5:53 PM • GlobeNewswire
A securities class action lawsuit has been filed against ARS Pharmaceuticals (SPRY) for allegedly providing false and misleading statements regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company allegedly misled investors about a July 1, 2026 coverage start date, causing shareholders to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.
09/22/2026, 2:48 PM • GlobeNewswire
Rosen Law Firm is reminding investors in Aardvark Therapeutics (AARD), UWM Holdings (UWMC), and ARS Pharmaceuticals (SPRY) of upcoming lead plaintiff deadlines in securities class action lawsuits. The lawsuits allege that defendants made materially false statements and failed to disclose material adverse facts about their businesses, with Aardvark specifically accused of overstating the safety and commercial prospects of its ARD-101 drug candidate.
09/18/2026, 9:39 PM • GlobeNewswire
A securities class action lawsuit has been filed against ARS Pharmaceuticals, Inc. (SPRY) for allegedly providing misleading statements to investors regarding the timeline for expanded insurance coverage of its epinephrine nasal spray product 'neffy' through CVS Caremark. The company reportedly made confident statements about July 1, 2026 coverage while concealing material adverse facts, causing investors to purchase securities at artificially inflated prices. The lead plaintiff deadline is October 5, 2026.
09/18/2026, 8:32 PM • GlobeNewswire
Rosen Law Firm announces securities class action lawsuits against HDFC Bank Limited and other companies. HDFC Bank is accused of camouflaging payments as marketing spend to pay higher interest to a state firm, with activities allegedly approved by senior management and potentially violating regulations. The lead plaintiff deadline for HDFC Bank is October 13, 2026. Investors who purchased securities during the specified class periods may be eligible for compensation.
09/18/2026, 8:18 PM • GlobeNewswire
Pomerantz Law Firm has filed class action lawsuits against ARS Pharmaceuticals, Inc. and other companies for alleged securities fraud. ARS's stock fell 23.91% after the company failed to secure expanded insurance coverage for its epinephrine nasal spray (neffy) through CVS Caremark by the July 1, 2026 deadline. Investors have until October 5, 2026 to join the class action.
09/15/2026, 6:11 PM • GlobeNewswire
Holzer & Holzer, LLC announces lead plaintiff deadlines for shareholder class action lawsuits against three companies: Pentair plc for alleged false statements regarding inventory destocking in its Pool channel (deadline October 2, 2026); Datavault AI Inc. for alleged misrepresentations about partnership value and trading activity (deadline October 5, 2026); and ARS Pharmaceuticals, Inc. for alleged false statements about insurance coverage timeline for its epinephrine nasal spray product (deadline October 5, 2026).
09/15/2026, 12:47 PM • GlobeNewswire
Schall, Brown & Schwartz LLP announced a securities fraud class action lawsuit against ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) for making false and misleading statements regarding timeline issues related to CVS Caremark's addition of neffy to its formulary. The class period spans March 9, 2026 to June 24, 2026, with a deadline of October 5, 2026 for investors to participate. The lawsuit alleges the company recklessly disregarded risks that could significantly impact insurance coverage guidance and commercialization of neffy.
09/15/2026, 10:00 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 10/01/2026
Company Profile
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.